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Abstract.  We studied binding and degradation of la- 
beled platelet thrombospondin (TSP) by normal and 
variant bovine aorta endothelial  (BAE) cells.  [125I]- 
labeled TSP bound to cells at 37~  in a  specific, 
saturable,  and time-dependent fashion.  Incubation of 
cell monolayers with fluoresceinated TSP resulted in 
punctate cellular staining,  but no staining of the ex- 
tracellular matrix.  Heparin,  fucoidan, chondroitin sul- 
fate, platelet factor 4,  beta-thromboglobulin, unlabeled 
TSP,  and  serum derived from whole blood all com- 
peted for binding of [~25I]TSP. [12Sl]TSP  was degraded 
to TCA-soluble radioactivity, which appeared in the 
medium after a 60-90-min  lag.  Degradation was in- 
hibited to the same extent as binding by increasing 
concentrations of heparin,  fucoidan, platelet factor 4, 
or whole blood serum.  Normal BAE cells bound and 
degraded less [t2q]TSP  than  variant BAE cells. The 
dissociation constants (Kas) for binding and the con- 
stants for degradation (Kms) for degradation by the two 
cell strains,  however, were similar (30-50 nM).  The 
inhibitory effects of heparin and platelet factor 4  were 
lost when the two inhibitors were present in a  1:1 
(wt/wt) ratio.  Treatment of suspended cells with tryp- 
sin or heparitinase caused less binding of TSP.  These 
results indicate that there is a  specific receptor for TSP 
on endothelial cells which mediates binding and degra- 
dation.  This receptor may be a  heparan  sulfate pro- 
teoglycan. 
T 
HROMBOSPONDIN (TSP) ~ is a high molecular weight 
(450,000)  glycoprotein  which  is  composed of three 
identical,  disulfide-linked,  polypeptide chains (12, 19, 
31,  32,  33,  39).  TSP  interacts  with  a  variety  of macro- 
molecules,  including  heparin  (17), thrombin  (13), fibrino- 
gen  (6,  16, 29, 34), fibronectin  (29, 30, 48), histidine-rich 
glycoprotein (35), plasminogen  (59), calcium ion (15, 32), 
type V collagen (48), and sulfatides (56, 57). TSP is a major 
component of platelet alpha-granules  and thus is secreted 
when platetets are stimulated  with thrombin or other agents 
(4). This TSP becomes associated with platelet surfaces and 
the meshwork of the fibrin clot (5, 18, 20, 21, 41, 49, 53, 62). 
High and low affinity interactions  of TSP with unstimulated 
and  stimulated  platelets  have recently been reported (64). 
TSP is synthesized by and deposited into the extracellular 
matrices of cultured endothelial  cells (25,  42, 45),  fibro- 
blasts (26), glial  cells (2),  and smooth muscle cells (55), 
among  others.  Immunofluorescence  microscopy  revealed 
more TSP in injured tissues than in stable normal adult tis- 
sues (63). Isolated matrices derived from cultured microvas- 
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1. Abbreviations  used in this paper:  BAE, bovine aorta endothelial; TSP, 
thrombospondin. 
cular endothelial  cells of adult dermis contained less TSP 
than matrices of neonatal foreskin microvascular endothelial 
cells (27). The regulation of TSP synthesis by cells in culture 
is modulated by factors affecting the cell cycle, as evidenced 
by observations that synthesis of TSP was greater in cultures 
of subconfluent cells than in cultures of density-arrested  cells 
(47)  and  was  transiently  enhanced  when  platelet-derived 
growth factor was given to serum-starved cultures (2, 36). 
TSP amplified the mitogenic effect of epidermal growth fac- 
tor towards vascular smooth muscle cells (37). Thus, TSP ap- 
pears to have important effects on cells, especially under con- 
ditions in which there is active tissue modeling or healing. 
The mechanisms  by which TSP has its effects on cells are 
unknown. 
A previous paper from our laboratory described binding 
of TSP to fibroblast monolayers and to isolated matrices de- 
rived from fibroblast cultures (40). Binding to the intact cell 
layers was transient,  and bound TSP was rapidly  degraded 
to a q'CA-soluble form (40).  Binding of radiolabeled TSP to 
the cell layers was not saturable because of extensive binding 
of TSP to extraceilular  matrix at higher TSP concentrations. 
However, degradation of radiolabeled  TSP was saturable and 
exhibited characteristics  of well-studied  examples of recep- 
tor-mediated  endocytosis (40).  In subsequent experiments, 
we found that bovine aorta endothelial  (BAE) cells could be 
used to study cellular binding and degradation  of TSP with- 
out the complication of binding of TSP to extracellular  ma- 
trix.  The matrix  formed by BAE cells is located primarily 
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sible to exogenous molecules as the matrix of cultured fibro- 
blasts.  The BAE culture system is of physiologic and patho- 
physiologic relevance because vascular  endothelium would 
be exposed to high concentrations of TSP during hemostatic 
and thrombotic events and perhaps also during neovascular- 
ization. We hypothesized, on the basis of previous studies 
(40),  that  heparin-like  molecules  functioned  as  thrombo- 
spondin  receptors.  The  heparan  sulfate  proteoglycans  of 
BAE cells have been well characterized (38, among others). 
Therefore,  we studied binding and degradation  of TSP by 
BAE cells  in considerable detail.  Both  events  seem to be 
mediated by a celt surface molecule which has the character- 
istics of a heparan  sulfate  proteoglycan. 
Materials and Methods 
Materials 
The  following  were  purchased:  DME  and Ham's  FI2  medium  (Gibco 
Laboratories,  Grand Island, NY); FBS (Hyctone Laboratories,  Sterile Sys- 
tems,  Inc,  Logan,  UT);  vitronectin (Calbiochem-Behring Corp.,  San 
Diego, CA); trypsin, BSA, fucoidan,  heparin (porcine intestinal mucosa), 
chondroitin sulfate, hyaluronic acid, and dextran sulfate (tool wt 500,000) 
(Sigma  Chemical  Co.,  St.  Louis,  MO);  hyaluronidase,  chondroitinase 
ABC, and heparitinase (Miles Laboratories, Elkhart, IN); FITC (Cappet 
Laboratories,  Cochranville, PA); rabbit antibodies to human factor VIII- 
related antigen (Dako Corp., Santa Barbara, CA, or Calbiochem-Behring 
Corp.); and rhodamine- or FITC-labeled  secondary antibodies (Jackson 
Laboratories,  Avondale, PA). Monoclonat antibodies to muscle-specific and 
smooth  muscle-specific actins (22) were provided  by Dr.  Allen Gown 
(University of Washington,  Seattle, WA). Carrier-free sodium  525I was ob- 
tained from New England Nuclear (Boston,  MA). 
Purification of TSP and Other Proteins 
TSP was purified from the reteasate of thrombin-stimulated human platelets 
by affinity chromatography  on heparin-agarose and gel filtration in the pres- 
ence of0A mM calcium chloride, according to a previously published pro- 
cedure (49). The purification  also resulted in good yields of platelet factor 
4 (obtained by eluting the heparin-agarose with 2 M sodium chloride) and 
beta-thromboglobulin  precursor (separated from TSP on the P-300 gel filtra- 
tion column) (49).  The amino terminal sequence of the beta-thrombo- 
globulin, kindly determined by Dr.  Karna Skortensgaard,  was predomi- 
nantly (>95%) Asn-Leu-Ala-Lys-Gly-Lys-Glu-Glu;  i.e., it contained four 
residues at the amino terminus which are largely missing from beta-throm.. 
bogtobulin obtained from outdated  platelets  (11). Fibronectin was purified 
from a plasma protein side fraction by heat precipitation and chromatogra-- 
phy  on DEAE-cellulose (44).  Fibrinogen was  purified  from plasma by 
precipitation  with ammonium sulfate,  followed by DEAE-cellulose chro- 
matography  (43). 
Preparation of  Iodinated and Fluoresceinated TSP 
TSP was iodinated with ~ZSl  by the chloramine T method (40) and repuri- 
fled  by affinity  chromatography on heparin-agarose in the presence of 
0.1 mM calcium chloride. The labeled protein was >96% precipitabte by 
10% "IV_A  and appeared intact on SDS-polyacrylamide gels (28) analyzed 
by autoradiography.  [t~I]TSP ranged from 0.2 to 1 gCi/l~g protein sp act. 
TSP was dialyzed against 0.05 M carbonate, pH 9.5, 0.15 M sodium chlo- 
ride, and conjugated to FITC at a concentration of 30 ~tg fluorochrome/mg 
protein for 1 h at 24~  with continuous gentle rocking. Free FITC was sepa- 
rated from FrI'C-TSP by dialysis against 0.01 M Tris chloride, pH 7.4, 0.15 M 
sodium chloride, 0.1 mM calcium chloride. Examination of FITC-TSP on 
SDS-polyacrylamide gels under ultraviolet illumination revealed a single 
fluorescent  band migrating at the same position as purified  TSP. 
Preparation of Whole Blood Serum and 
Plasma-derived Serum 
Sera were prepared from blood obtained from a volunteer donor and placed 
in a glass tube containing no additive or a polypropylene tube containing 
acid citrate-dextrose  (60). Whole blood serum was prepared by centrifuga- 
tion of the retracted clot in the glass tube after incubation for 3 h at room 
temperature.  Plasma in acid citrate-dextrose was collected by centrifugation 
at 2,400 g for 1 h at 4~  Remaining platelets were removed by centrifuga- 
tion for 3 min in a microfuge.  The plasma was clotted for 60 rain at 370C 
by addition of calcium chloride to a final concentration of 20 mM. Serum 
was separated  from the clot by centrifugation. Neither whole blood nor 
plasma-derived serum was cytotoxic in assays in which BAlE  cells were in- 
cuhated for 2 d in media containing the sera at 10% concentration. TSP con- 
centrations in the sera, determined by quantitative  ELISA  (26),  were as 
follows:  whole  blood  serum,  23.3  ~tg/ml; and  plasma-derived  serum, 
0.82 ~tg/ml. 
Cells 
Normal and variant BAE cells (gifts of Dr. Robert Auerbach, University of 
Wisconsin) were isolated from aortas obtained at local abbatoirs using col- 
lagenase according to an established protocol (9) and initially characterized 
by the method of Voyta et al. (61). Cells were cultured in DME containing 
4,500 rag/liter glucose, 2 mM glntamine, and 20% FBS and were used be- 
tween passages 6 and 12. Human foreskin fibroblasts  (provided by Dr. B. 
Lynn Allen-Hoffman,  University of Wisconsin) were cultured in Ham's FI2 
medium supplemented with 15 % FBS. 
Both normal and variant BAE cultures stained for factor VIII-related an- 
tigen and sorted as one peak when stained with t,t-dioetedecyl-3,3,3',Ytetra- 
methyl indocarbocyanine perclorate-labeled acetylated low density lipopro- 
rein  (DiI-Ac-LDL)  and analyzed  by  fluorescence-activated  cell  sorting 
(kindly performed by Dr. Robert Auerbach's laboratory) (61). Cells were 
negative when stained with antibodies speeifie for muscle and smooth mus- 
cle celt actins (22). These results indicated that both of our cultures were 
endothelial cells without detectable contamination with smooth muscle 
cells.  Normal  BAE  cells  have  a  typical  cobblestone  morphology  at 
confluence (Fig.  1 a), whereas the variant BAE cells had an atypical mor- 
phology consisting of cords of noncontact-inhibited cells which piled up 
above and around the cobblestone monolayers  upon reaching confluence 
(Fig.  1 b). The relative number of variant cells in preconfluent and newly 
confluent cultures remained constant with the passage number. The variant 
BAE cells appear to differ from the "sprouters" described by Sehgartz (58) 
in that the elongated cells in the cords were present in preconfluent  and 
newly confluent cultures, whereas sprout cells appear in cultures  main- 
tained  afar  confluence.  When the  normal  BAE  strain  was  kept  past 
confluence,  cells exhibiting typical sprouting morphology were observed. 
When doing binding or degradation assays (see below), cells in replicate 
plates were enumerated in a microscopic counting chamber after trypsini- 
zation. 
Fluorescence Microscopy 
Cells were grown to confluence on glass coverslips  and fixed with 100% 
methanol for 5 rain at -20~  Cells were stained for the presence of factor 
VIII-related antigen using rabbit polyelonal antibodies to human factor 
VIII-related antigen at either a  1:50 (Dako Corp.) or 1:100 (Calbiochem- 
Behring Corp.) dilution in the presence of 0.1% ovalbumin.  Cells were 
washed three times with 0.01 M Tris-buffered  saline, pH 7.2,  and stained 
with FITC-labeled goat anti-rabbit  IgG antibody. Murine monoclonal anti- 
bodies to muscle-specific  and smooth muscle-specific actins were used at 
the dilutions suggested by Dr. Gown and detected with a secondary FITC- 
labeled antibody against mouse IgG. Coverslips were mounted onto glass 
slides using 50% glycerol and examined by epifluorescence  using a Nikon 
Optiphot microscope equipped with a UFX-II camera. 
Cells were incubated with DiI-Ac-LDL at 10 l~g/ml for I-4 h at T/*C in 
a 5 % CO2 atmosphere, rinsed, and fixed according to the protocol of Voyta 
et al. (61). Coverslips were mounted and examined by fluorescence micros- 
copy using excitation and barrier filters appropriate for rhodamine fluores- 
cence.  Cells on coverslips  were also incubated with FITC-labeled  TSP at 
10 ~tg/ml at 37~  in 5% CO2 under various conditions.  Coverslips  were 
washed with DME with 0.2% BSA before fixation with 4% paraformalde- 
hyde in 0.t M phosphate buffer, pH 7.4. 
Binding Assays 
Binding assays were performed on confluent monolayers  in 35-ram tissue 
culture dishes as follows. Monolayers were rinsed twice with DME contain- 
ing 0.2% BSA, 1 ml of a binding mixture containing [ml]TSP and unla- 
beled TSP in DME containing 0.2% BSA was added, and cells were in- 
cubated at either 37 or 4~  for the appropriate time.  At the end of the 
The Journal of Celt Biology, Volume 105, 1987  1604 Figure 1. Microscopy of cultured BAE cells. (a) The normal strain of endothelial cells at confluence with typical cobblestone morphology. 
(b) The variant strain of endothelial cells at confluence: central foci of cobblestone cells are surrounded by cells in multiple layers of cords 
(arrows). (c) Binding of FITC-TSP to monolayers of normal endothelial cells after incubation for 4 h at 37~  showing punctate distribution 
of labeled protein. Monolayers of variant BAE cells showed similar, but more intense, punctate cellular staining. Cells incubated with FITC- 
TSP in the presence of 10 t~g/ml heparin had no staining (not shown). (d) BAE cells incubated with 10 gg/ml FITC-TSP for 60 min, followed 
by further incubation for 3  h  in binding medium without labeled TSP.  Bars,  100  ~tm. 
incubation, cell layers were washed 4 times with ice-cold DME containing 
0.2% BSA and solubilized overnight with 1 ml 1 N sodium hydroxide. Solu- 
bilized material was removed,  and plates were washed with an additional 
1 ml of 1 N sodium hydroxide. The radioactivity in the pooled extracts was 
then determined using a gamma counter. 
Binding assays were performed on cells in suspension in some experi- 
ments.  Monolayer cells at confluence were harvested with either 2.2 mM 
EDTA or EDTA and various concentrations of trypsin as described below, 
pelleted by centrifugation, and resuspended  in DME containing  0.2 % BSA. 
After resnspension, cells were greater than 97%  viable as determined by 
dye exclusion with Trypan blue.  Cells (0.5-1  x  106/100 Ixi) were added to 
microfuge  tubes containing a  1-ml mixture of DME,  0.2%  BSA,  ~25I- 
labeled TSP, and the appropriate amount of unlabeled TSP. The microfuge 
tubes ware precoated with 2 % BSA to minimize nonspecific binding.  The 
suspensions were  incubated at 37~  in 5% CO2 with frequent inversion. 
At the end of the incubation period, cells were pelleted by centfifugation 
for 2 min in a microfuge (Eppendorf, Brinkmann Instruments, Inc., West- 
bury, NY). Medium was removed,  and the cell pellets were put on ice and 
washed three times with ice-cold DME containing 0.2 % BSA with minimal 
disturbance of the pellets.  Radioactivity  remaining in the cell pellet was 
measured. 
Nonspecific binding was routinely determined in the presence of I lag/ml 
heparin rather than with an excess of unlabeled TSP (see Results).  In no 
instance did binding of radioactivity  to the tissue culture plates in the ab- 
sence of heparin and cells exceed the nonspecific  binding in the presence 
of heparin and cells.  All samples were run in duplicate,  Each experiment 
was performed a minimum of two times. 
Enzymatic Pretreatment of  Cells 
Cells to be treated with enzymes before  suspension binding assays were 
released from confluent rnonolayers with 2.2 mM EDTA and resuspended 
in DME containing 0,2%  BSA. Aliquots of cells in l-ml vol were then 
treated at 37~  for either 5 min with increasing concentrations of trypsin 
or for 3 h with heparitinase, chondroitinase ABC, or hyaluronidase  diluted 
in DME containing 0.2%  BSA, The reaction was stopped by pelleting the 
cells in a microfuge,  removing the enzyme in the supernatant, and washing 
the pellet once with DME containing 0.2% BSA. When trypsin was used, 
a fivefold excess (wt/wt) of soybean trypsin inhibitor was added before cen- 
trifugation. Cells were gently resuspended in DME containing 0.2%  BSA 
and used  in the binding assays  described above.  Aliquots of cells were 
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Figure 2.  Time course of binding of TSP to endothelial cells in 
monolayer. Normal  (A)  and  variant (B) endothelial cells  were 
grown to confluence in 35-ram culture dishes and incubated for 
varying  times  with  1 I~ml  ~2~l-labeled TSP. At  various  time 
points, the plates were washed, and bound TSP was extracted with 
1 N  sodium  hydroxide  as  described  in  Materials  and  Methods. 
Binding  in  the presence  of  1 Ixg/ml  heparin  (o)  was  subtracted 
from the total binding in the absence of heparin (e) to determine 
the specific binding of [~z'~IITSP to the cell layers (A). 
checked for viability by the Trypan blue exclusion method,  Control ceils 
were treated by the same protocols, except that the enzymes were omitted. 
Assay of  Degradation 
Degradation of [~2~I]TSP was determined from the amount of radioactivity 
in the medium which became soluble in  10% TCA after incubation with 
cells (40)~ Duplicates of each experimental point were done.  Degradation 
was monitored during a time period when the degradation  was linear. 
Results 
Localization of  FITC-TSP  Bound to BAE Cells 
BAE cells were incubated with 10 lag of FITC-labeled TSP 
at 37~  for different periods of time, washed, fixed, and ex- 
amined by fluorescence microscopy to determine the local- 
ization of TSP bound to cells in monolayer. Staining was pri- 
marily in a punctate pattern  with no detectable binding to 
fibrillar  matrix  (Fig.  1  c).  Addition of  10  lag/ml  heparin 
simultaneously  with  FITC-TSP  blocked  binding.  Little 
FITC-TSP was seen when cells were incubated for 1 h with 
FITC-TSP,  washed, and incubated an additional 3  h in the 
absence of FITC-TSP (Fig.  1 d). 
Time Course of  Binding of TSP to Cells 
Binding of [eSI]TSP to normal BAE ceils  at 3"/~  rapidly 
increased over the first  15 min and remained fairly constant 
for up to 4 h (Fig. 2 A). Binding to variant BAE cells reached 
Table I. Inhibitors of [12511TSP Binding to Endothelial 
Cell Monolayers 
Range of 
Competitor  EDS0*  concentrations tested 
Thrombospondin  25-50 ~tg/ml  0.1-100  p~g/ml 
Fucoidan  0.05-0.1  ~glml  0,01-1  Ixglml 
Heparin  0.1  lagfml  0.001-1  gg/ml 
Chondroitin sulfate  50 ltg/ml  0.1-100  Ixg/ml 
Dextran sulfate  >10 I~g/ml*  0. t-10 ~tg/ml 
Hyaluronic acid  >100 Ixg/ml*  0.1-100 ~glml 
Beta-thromboglobulin  1 ~tg/ml  0.1-50  ~tglmi 
Platelet factor 4  1-5 Ixg/ml  0.1-50 I,  tg/ml 
Fibronectin  >50 ~tg/ml~  0.1-50 I~g/ml 
Vitronectin  >20 ~tg/mlt  0.1-20 I~g/ml 
Fibrinogen  >100 ~tglmit  0.1-100  Ixg/ml 
Whole blood serum  2%  0.2-10% 
Plasma-derived  sertma  >10%  0.2-10% 
* Concentration of competitor giving 50% inhibition  of total binding of 0. l lag/ 
ml  [~"~I]TSP to variant endothelial cell monolayers (1  x  106 cells) after a 
60-min incubation at 37~  The experiment with beta-thromboglobulin was 
done with 1.0 ~g/ml [~2~I]TSP. 
No inhibition was seen at these concentrations. 
a maximum between 45 and 60 rain and decreased thereafter 
(Fig. 2 B). Degradation of [uSI]TSP by normal BAE cells, 
as monitored by the appearance of TCA-soluble radioactivity 
in the medium, was first detected at 60 min. The amount of 
TCA-soluble radioactivity increased linearly over the next 
3 h (not shown). Degradation of  labeled TSP by variant BAE 
cells was apparent by 45 min of incubation at 37~  and in- 
creased linearly for the next 3 h (not shown). Binding to both 
cell types at 4~  was maximal at 120 min; no degradation 
was evident at this temperature (not shown). 
Inhibition of TSP Binding by Various  Macromolecules 
Increasing amounts of unlabeled TSP competitively inhib- 
ited binding of [t25I]TSP to cells in monolayer (Table I) or 
I00 ~  ~ 
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6o 
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Figure 3. Inhibition of binding and degradation of TSP by heparin 
and fucoidan.  Variant endothelial cells were incubated with labeled 
I laglml TSP for 60 or 240 min at 37~  in the presence of increasing 
amounts of heparin (e, o) or fucoidan  (,i,, A), and binding after 
60 min (A,  e) and degradation  between 60 and 240 rain (A, O) 
were  determined.  The  amount  of 'l'CA-soluble  products  in  the 
medium after 60 min was subtracted  from the amount after 240 
min, and degradation was calculated for the intervening 180 min. 
Results are expressed as  %  of the anaount  of [~25I]TSP bound or 
degraded  in the absence of heparin or fucoidan. 
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Figure 4. Effect of platelet factor 4 on the binding and degradation 
of TSP. (A) Variant endothelial cells were incubated for 60 min at 
37~  with labeled 0.1 pg/ml TSP; platelet factor 4 at concentrations 
ranging from 0.1 to 50 Ixg/ml, and no heparin (o,  ), or 1 lag/ 
ml heparin (o, -  -  -). Cell layers were then washed, and bound. 
[~25I]TSP was extracted and quantified. (B) Degradation of [~25I]TSP 
in the medium to TCA-soluble products was determined as de- 
scribed for Fig. 3. The medium contained labeled TSP, increasing 
amounts of platelet factor 4, and no heparin (i,  ), or heparin 
(A,  -  -  -) as in A. 
suspension (not shown). In competition assays, 100 lxg/ml of 
unlabeled TSP inhibited binding of labeled TSP, 0.1 IJg/ml, 
to monolayers by 65 %. Several other molecules, including 
heparin, fucoidan, platelet factor 4, and beta-thromboglobu- 
lin, also inhibited binding of labeled TSP to cells (Table I). 
Heparin at a concentration as low as 0.10 I~g/ml competed 
for 50%  of the binding of 0.1  I~/ml [=SI]TSP to  1  ￿  106 
cells in monolayer (Fig. 3). Treatment of monolayers with 
heparin resulted in prompt (<15 rain) release into the med- 
ium of 80%  of the labeled TSP that had bound over the 
preceding 60 rnin (not shown). Fucoidan, which was shown 
previously to be an inhibitor of TSP binding to sulfatides of 
erythrocyte  membranes (51), was more effective  than heparin 
in blocking the binding of [t25I]TSP to cells (Fig. 3). Chon- 
droitin sulfate, at a considerably higher concentration than 
heparin or fucoidin, inhibited binding, whereas dextran sul- 
fate and hyaluronic acid did not (Table I). Platelet factor 4, 
which was shown previously to bind specifically to endothe- 
lial cells (10), inhibited total binding of TSP by ~70% (Fig. 
4 A). Platelet factor 4 and heparin had no inhibitory effect 
when present at an 1:1 (wt/wt) ratio (Fig. 4 A). Beta-throm- 
boglobulin was as effective as platelet factor 4 in inhibiting 
of TSP binding to variant endothelial cells (Table I). Beta- 
Table II. Scatchard Analysis of Binding of [;2Sl]TSP by 
Cells in Monolayer 
Cell type  n  Kd  Binding sites/cell 
nM  (x  10  -5) 
BAE  3  43  -1-  30  5.1  +  3.8 
BAE variant  4  45  +  12  30  +  14 
Fibroblasts  2  Not saturable  Not saturable 
n,  number  of separate experiments.  The  SD  is given  for experiments  done 
more than twice. 
thromboglobulin and heparin did not neutralize one another 
as inhibitors in the TSP-binding assay (not shown). 
Whole blood serum was more effective  than serum derived 
from platelet-poor plasma (plasma serum) in blocking TSP 
binding to cells (Table I). As determined by ELISA, plasma 
serum had a  TSP concentration 25-fold lower than whole 
blood serum. The differences in platelet factor 4 and beta- 
thromboglobulin concentrations between plasma serum and 
whole blood serum, determined by commercial radioimmu- 
noassay kits, were even greater (data not shown). Fibrinogen 
and fibronectin, plasma proteins that are known to interact 
with TSP, did not compete for binding of TSP to cells (Table 
I). Vitronectin also did not compete with TSP for binding to 
cells (Table I). 
Saturation of  Binding of TSP to Cells in Monolayer 
[t2SI]TSP bound to both normal (Fig.  5) and variant (data 
not shown) BAE cells in a saturable manner. Binding to fi- 
broblast monolayers, done in parallel assays, was not satura- 
ble. The two BAE cell strains had similar dissociation con- 
stants  (KdS) as determined by Scatchard analysis,  but the 
variant strain cells had sixfold more binding sites (Table II). 
These estimations of binding kinetics assume that one mole- 
cule of TSP binds to one binding site, assume that heparin 
will compete for all specific binding, and ignore the contri- 
bution  of internalized  TSP.  Inasmuch  as  >80%  of cell- 
associated  TSP  was  promptly  released  upon  addition  of 
heparin, the contribution of internalized TSP to the calcula- 
tion of the number of binding sites/cell was small. 
Degradation of TSP 
The degradation of [12SI]TSP  by cells at 37~  was estimated 
by the increase in TCA-soluble radioactivity in the medium 
at 240 rain as compared with 60 rain. The velocity of  degrada- 
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Figure 5. Saturation of binding of TSP to normal en- 
dothelial cells in monolayer. (A) The binding assay 
was performed as described in Materials and Meth- 
ods.  Normal  endothelial  cells  ('x,  llY  i  cells/35-mm 
dish) were incubated for 60 min at 37~  with increas- 
ing concentrations of a mixture of labeled and unla- 
beled TSP (25 cpm/ng sp act). Specific binding of  TSP 
(i) was calculated by subtraction of the amount of 
[t~I]TSP bound in the presence of I I.tg/ml  heparin (o) 
from the amount bound in the absence of heparin (e). 
(B) Scatchard analysis of the specific binding data. 
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Figure 6,  Degradation of TSP by normal endothelial cells  in 
monolayer. (A) Degradation of increasing concentrations of TSP 
(25 cpm/ng sp act) by cells in monotayer was monitored between 
60 and 240 min as described for Fig. 3. Specific  degradation  of  TSP 
(A)  was  calculated by  subtraction of the  amount of [125I]TSP 
degraded in the presence of I lag/ml  heparin (o) from the amount 
degraded in the absence of  heparin (e). (B) Data replotted to deter- 
mine the kinetics of turnover by Lineweaver-Burke  analysis. 
tion was linear over this interval. Degradation of TSP by the 
two endothelial cell strains,  and also by fibroblasts,  was 
saturable and amenable to analysis by Lineweaver-Burke 
plots (Fig. 6). The V~x of normal BAE cells in monolayer 
was t3-fold less than the V,~ of variant BAE ceils although 
the constants of degradation (Kms) were similar (Table UI), 
When normal BAE cells were incubated with TSP for 60 
min, washed, and incubated without TSP, 50% of bound TSP 
was degraded in •2  h (not shown) and 80% of bound TSP 
was degraded in 5 h. Degradation was partially inhibited by 
monensin or chloroquine at  10  "~ M  (not  shown).  When 
degradation was inhibited by the lysomotropic agents, label 
accumulated in the cell layer. As described above, degrada- 
tion was not detectable in cultures incubated at 4~ 
As shown in Table III, the/(ms obtained by Lineweaver- 
Burke analysis closely corresponded to the/Gs of binding 
for the two endothelial cell strains. Agents which inhibited 
binding of TSP to cells also inhibited degradation of TSP 
with parallel dose-response curves. This was true for hepa- 
rin or fucoidan (Fig. 3), platelet factor 4 in the presence or 
absence of heparin (Fig. 4), and serum derived from whole 
blood or platelet-poor plasma (not shown). 
Biruling of  TSP by Cells in Suspension 
Cells released from the substratum with trypsin, 500 [tg/ml, 
and 2.2 mM EDTA were allowed to repair from the trypsin 
treatment for 30--40 min and then assayed for binding of 
[z2q]TSP. TSP binding to BAE cells and fibroblasts  sus- 
pended in this manner was saturable. The BAE cells had 
Kas that were 5-10-fold  higher in affinity as compared to 
cells in monolayer (Table IV). There were less binding sites 
on the suspended cells than on the monolayer cells. Variant 
BAE cells at 4~  bound TSP with the same kinetics as vari- 
ant BAE cells at 37~ 
Sensitivity of TSP,  binding Sites to Enzymatic Digestion 
Variant  BAE  cells  which  were  suspended with 2.2  mM 
EI~A and no trypsin had binding constants similar to variant 
BAE cells in monolayer (Table IV). Normal BAE cells could 
be released from the substratum with EDTA alone but did 
not exhibit saturable binding in suspension binding after re- 
lease. 
When EDTA-suspended cells were treated for 5 min with 
trypsin, washed, and then incubated with 2.2 nM [~25I]TSP 
(1 ~ml), the trypsin treatment was found to cause decreases 
in the binding of TSP at trypsin concentrations as low as 50 
I.tg/ml ffig. 7). Treatment of cells with increasing doses of 
heparitinase for 3 h at 37~  also resulted in a decrease in the 
binding of TSP to the cells (Fig. 7), When cells were first 
expose(, to trypsin and then to increasing doses of heparitin- 
ase, there was not an additive reduction in binding (Fig. 7). 
There was no proteolytic degradation of labeled TSP by 
heparitinase when the ligand was treated with enzyme in so- 
lution and then analyzed by PAGE followed by autoradiogra- 
phy (not shown).  Treatment of cells with chondroitinase 
ABC (Fig. 7) or hyaluronidase (not shown) did not reduce 
the amounts of TSP bound to cells in suspension. Cells in 
monolayer also showed dose-dependent reduction of TSP 
binding when pretreated with heparitinase. This was most 
evident when the cells were incubated with 10 lxg/ml cyclo- 
heximide both during the enzyme treatment and during the 
subsequent binding assay. Such treatment resulted in 53 % 
reduction of binding. 
Discussion 
[~2SlITSP bound  to  monolayers of endothelial cells  in  a 
specific  and  saturable  manner  indicative  of a  receptor- 
mediated process.  The binding was  primarily to the en- 
dothelial cells themselves, as assessed by fluorescence mi- 
croscopy of  bound FITC-TSP, with very little, if  any, binding 
to matrix. Most of the [L~q]TSP bound to BAE monolayers 
after a short incubation was released promptly when the cell 
layers were washed and incubated further with heparin. If 
heparin was absent during the second incubation, most of  the 
bound TSP was degraded to "l'CA-soluble products, Thus, the 
results with endothelial cells were different from the results 
with fibroblast cultures, in which 40-50%  of TSP binding 
was to a slowly turning-over extracellutar matrix pool (40). 
The difference between fibroblasts and endothelial cells in 
monolayer is most likely due to differences in the types and 
location of extracellular matrix. BAE cultures have less ex- 
tensive matrix formation than fibroblast cultures, and the 
bulk of the endothelial cell matrix is not accessible to exoge- 
nous proteins because it is located on the basal side of the 
cells. We were able to demonstrate saturability of [~2Sl]TSP 
binding to suspended human foreskin fibroblasts or normal 
BAE cells stripped of extracellular matrix by trypsinization 
(Table IV), whereas binding to monolayer fibroblasts or to 
normal BAE cells suspended with EDTA in the absence of 
Table III. Lineweaver-Burke  Analysis of  Degradation of 
[I2SI]TSP by Cells in Monolayer 
Cell type  n  K.~  V,~., 
nM  (molecules~cell  per rain  x  10  -3) 
BAE  2  30  3,3 
BAE variant  2  48  45 
Fibroblasts  2  68  16 
n, number of separate experiments. 
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by Cells in Suspension 
Method of  Binding sites/ 
Cell type  n  Temperature  harvest*  K~  cell 
C ~  nM  (x  10  -s) 
BAE  2  37  T-EDTA  10,8  1.0 
BAE variant  3  37  T-EDTA  4.6  +  0,7  2,5  _+  0.5 
BAE variant  2  4  T-EDTA  4.4  2,9 
BAE variant  1  37  EDTA  15.5  32 
Fibroblasts  3  37  T-EDTA  4.7  _+ 3.1  2,6  •  0.2 
n, number of separate experiments, The SD is given for experiments done 
more than twice. 
* Cells were  harvested from monotayers with 0,05%  trypsin and 0,5  mM 
EDTA  (T-EDTA)  or  with  2.2  mM  EDTA  and  no  trypsin  (EDTA)  and 
resaspended in medium for suspension assay as described in Materials and 
Methods. 
trypsin was not saturable. As discussed below, however, TSP 
may bind to molecules on trypsinized cells in suspension 
which are different from the molecules which mediate bind- 
ing and degradation of TSP by cells in monolayer. 
Degradation of  TSP by eudothelial cells was saturable and 
inhibited by chloroquine or incubation of cells in the cold, 
as has been previously described for degradation of TSP by 
fibroblasts (40). The following observations indicate that the 
cellular moiety which mediates binding of TSP by endo- 
thelial cells in monolayer at 37~  also mediates degradation 
of TSP: Kds of binding were the same as the K,~s; the vari- 
ant BAE cells both bound more TSP and degraded more TSP 
as compared to the normal cells; and binding and degrada- 
tion of TSP were suppressed in parallel by a number of ex- 
perimental conditions. Binding constants were estimated un- 
der less than ideal conditions. We were limited in the amount 
of TSP we could purify, and some of  our preparations of TSP 
aggregated at concentrations >100 lag/ml when >0.5 mM cal- 
cium ion was present. Therefore, we could not routinely use 
an excess of unlabeled TSP to estimate nonspecific binding 
and instead defined specific binding as that inhibited by hepa- 
fin. The cultures would be expected to accumulate a small 
amount of endogenous TSP during the assays (42) because 
protein synthesis w~s not blocked; the possible contribution 
of this TSP was ignored. Nevertheless, we were able to ob- 
tain reproducible and self-consistent results (Table  II).  In 
particular, the Ks of binding (45 nM, Table II) agreed well 
with the concentrations of unlabeled TSP that caused 50% 
inhibition of binding of labeled TSP (55-110 nM, Table I). 
Heparin,  fucoidan, platelet factor 4,  and beta-thrombo- 
globulin all caused less binding and degradation of TSP by 
cells. Chondroitin sulfate also inhibited binding and degra- 
dation of TSP, although higher concentrations were required. 
Dextran sulfate and hyaluronic acid did not inhibit. These 
results differ from experiments reported by Roberts et al. 
(56), in which heparin, fucoidan, and dextran sulfate, but not 
chondroitin sulfate, inhibited binding of TSP to sulfatides. 
Three adhesive proteins known to bind to TSP and/or to 
cells, (i.e., fibrinogen, fibronectin, and vitronectin) did not 
inhibit binding of TSP. Thus, the interaction of TSP with 
cells is probably independent of the interactions of cells with 
the adhesive proteins. The inhibitor), effect of whole blood 
serum on binding and degradation of TSP is likely a sum of 
the inhibitory effects of platelet factor 4 and beta-thrombo- 
globulin, inasmuch as the combined concentration of these 
2 proteins in whole serum is ~20 Ixg/ml (46). 
The major TSP-binding site on endothelial cells was sensi- 
tive to digestion by trypsin or heparitinase. Chondroitinase 
ABC and hyaluronidase had no effect. A decrease in binding 
of platelet factor 4  to endothelial cells after heparitinase 
treatment has also been reported (10). No additive decrease 
in TSP binding was observed in cells which were treated with 
both trypsin and heparitinase. This result suggests that the 
trypsin-sensitive binding site is the same as the heparitinase- 
sensitive binding site.  The higher affinity, lower capacity 
sites that were unmasked when suspended cells were treated 
with  trypsin and/or  heparitinase  may  involve molecules, 
such as sulfatides, distinct from those that mediate binding 
to cells in monolayer. 
The  inhibitory effects  of heparin,  heparin-binding pro- 
teins, and heparitinase all point to a heparinqike molecule 
on the endothelial cell surface as a  receptor for TSP.  Re- 
cently, we had the opportunity to study the binding and 
degradation of TSP by Chinese hamster ovary (CHO) cell 
mutants defective in  glycosaminoglycan biosynthesis and 
found that mutants lacking heparan sulfate were unable to 
bind or degrade TSP (50 and Murphy-Ultrich, J. E., L. G. 
Westrick, J. D. Esko, and D. E  Mosher, manuscript submit- 
ted for publication). Thus, we think that the TSP receptor on 
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Figure 7. Effects  of  enzymatic treatment on the ability 
of endothelial cells to bind TSE Variant endothelial 
cells were released from monolayer with 2.2 mM 
EDTA and resuspended in DME containing 0.2% 
BSA. Aliquots of the suspension were treated at 37~ 
for 5 min with increasing concentrations of trypsin 
(~x) or for 3 h with increasing concentrations of chon- 
dmitinase ABC (Ha) or heparitinase (e) according to 
the protocol described in Materials and Methods. In 
addition, cells were released from monolayer with 50 
t~g/ml trypsin and 0.5 mM ED'fA before treatment 
with increasing concentrations of heparitinase (o). 
Enzyme-treated ceils and controls were incubated in 
suspension with labeled 1 Ixg/ml  TSP for 60 min at 
37~  and the bound fraction was separated as de- 
scribed in Materials and Methods, Results are ex- 
pressed as % of [12~I]TSP bound to cells not treated 
with an enzyme. 
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can, probably an integral membrane molecule such as that 
described by Rapraeger  et al.  (54).  At present, we do not 
know how to relate our findings to those of Asch et al. (1). 
These authors  presented several  kinds of evidence that the 
88,000-mol-wt glycoprotein recognized by a commercially 
available  monoclonal antibody,  OKM5,  mediated the bind- 
ing  of TSP to human  platelets,  C32  melanoma cells,  and 
HT1080 fibrosarcoma cells. 
We fortuitously found a stable morphologic variant of BAE 
cells which also was variant for the metabolism of TSP. Im- 
munofluorescence studies of factor Vl/I-related antigen, Dil- 
Ac-LDL, and muscle specific actin and electron microscopy 
all  indicated that  the variants  were endothelial  cells.  The 
variant strain arose spontaneously  in the laboratory  of Dr. 
Robert Auerbach.  It is not known if these cells represent a 
satellite population of aortic endothelial cells which is pres- 
ent normally in vivo. 
Endothelial cells have been shown to have receptors for 
many different molecules, including heparin (23), thrombin 
(3), platelet factor 4  (10),  antithrombin  HI (38), fibrinogen 
(14),  beta-thromboglobulin (24),  multiplication stimulating 
factor (insulin-like growth factors  1 and 2) (8), and insulin 
(7), among others.  In the present studies,  we provide evi- 
dence for the existence of a receptor on endothelial cells for 
TSP. The binding of TSP to this receptor must be short-lived, 
because bound molecules were rapidly degraded. At the very 
least,  the receptor would be expected to mediate efficient 
clearance of TSP in vivo. Mumby et al. (47) have shown that 
the  synthesis  of TSP is affected by cell density  and  is in- 
creased in subconfluent cells as compared to confluent cells 
in  monolayer.  Other investigators  have  reported  that  TSP 
synthesis by  smooth muscle and glial cells is inducible by 
platelet-derived growth factor (2,  36).  Preliminary experi- 
ments from our laboratory suggest that binding and degrada- 
tion of TSP, like TSP synthesis,  is significantly elevated in 
subconfluent cultures as compared to confluent monolayers 
(data not shown). Thus, TSP may interact with the cellular 
receptor in a temporally specific manner and function as an 
effector or regulatory  molecule to control cell division. The 
interaction, furthermore, may be subject to complex modu- 
lation  inasmuch  as molecules packaged  alongside  TSP  in 
platelet alpha granules (platelet  factor 4, beta-thromboglob- 
ulin, and platelet heparitinase [52]) decreased the binding of 
TSP to endothelial ceils. Thus, binding of TSP to endothelial 
cells immediately after platelet release may be transiently 
blocked. 
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